Literature DB >> 10189256

Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity.

K Venkatakrishnan1, L L von Moltke, D J Greenblatt.   

Abstract

Phenacetin O-deethylation, widely used as an index reaction for cytochrome P450 1A2 (CYP1A2) activity, displays biphasic kinetics in human liver microsomes. CYP1A2 has been identified as contributing to the high affinity component, but is not verified as the sole contributor to the high affinity phase. In addition, the human CYP isoforms accounting for the low affinity phase have not been identified. We have used heterologously expressed human CYP isoforms to identify, kinetically characterize, and predict the relative contribution of the major human liver CYP isoforms mediating phenacetin O-deethylation. CYP1A2 (Km 31 microM) is the only high affinity phenacetin O-deethylase in human liver microsomes, while CYPs 2A6 (Km 4098 microM), 2C9 (Km 566 microM), 2C19 (Km 656 microM), 2D6 (Km 1021 microM), and 2E1 (Km 1257 microM) all contribute to the low affinity phase of the reaction. Considering the relative abundance of the various CYPs in human liver, CYP1A2 accounts for 86% of net reaction velocity at a substrate concentration of 100 microM, while CYP2C9 becomes the primary phenacetin O-deethylase at substrate concentrations of 865 microM and higher and accounts for 31% of the net Vmax of the reaction. Predictions from kinetic studies on heterologously expressed CYPs are consistent with chemical inhibition studies on human liver microsomes with sulfaphenazole and alpha-naphthoflavone that suggest a greater role for CYP2C9, and a smaller role for CYP1A2, at higher substrate concentrations. Thus CYP1A2 is the only high affinity human liver phenacetin O-deethylase, thereby validating the use of the high affinity component as an index of CYP1A2 activity in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10189256     DOI: 10.1021/js980255z

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

1.  Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.

Authors:  Kyoung-Ah Kim; Jaegul Chung; Dong-Hae Jung; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2004-09-08       Impact factor: 2.953

Review 2.  Substrate binding to cytochromes P450.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  Anal Bioanal Chem       Date:  2008-07-13       Impact factor: 4.142

3.  The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction.

Authors:  Pius S Fasinu; Patrick J Bouic; Bernd Rosenkranz
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-06-04

4.  CYP2E1 metabolism of styrene involves allostery.

Authors:  Jessica H Hartman; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

5.  Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction.

Authors:  Snehasis Jana; Himanshu Rastogi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

6.  Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients.

Authors:  Tongmeng Yan; Linlin Lu; Cong Xie; Jiamei Chen; Xiaojuan Peng; Lijun Zhu; Ying Wang; Qiang Li; Jian Shi; Fuyuan Zhou; Ming Hu; Zhongqiu Liu
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

7.  Fundamentals of Enzyme Kinetics: Michaelis-Menten and Non-Michaelis-Type (Atypical) Enzyme Kinetics.

Authors:  Eleanore Seibert; Timothy S Tracy
Journal:  Methods Mol Biol       Date:  2021

8.  Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.

Authors:  L L Von Moltke; D J Greenblatt; B W Granda; S X Duan; J M Grassi; K Venkatakrishnan; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

9.  Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

Authors:  Pallabi Mitra; Jürgen Venitz; Yunyun Yuan; Yan Zhang; Phillip M Gerk
Journal:  Drug Metab Dispos       Date:  2011-06-17       Impact factor: 3.922

10.  Cooperative effects for CYP2E1 differ between styrene and its metabolites.

Authors:  Jessica H Hartman; Gunnar Boysen; Grover P Miller
Journal:  Xenobiotica       Date:  2013-01-18       Impact factor: 1.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.